FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138899612> ?p ?o ?g. }

• W2138899612 endingPage "e822" @default.
• W2138899612 startingPage "e816" @default.
• W2138899612 abstract "Objective Evaluation of the efficacy and tolerability of transarterial chemoembolization with gemcitabine in patients with inoperable liver metastases of breast cancer. Materials and methods Open-label, prospective non-randomized single-center study design; patients had previous chemotherapy including anthracyclines and/or taxanes in the metastatic setting, adequate bone marrow reserve, sufficient liver/renal function, no centralnervous system metastases, Karnovsky-performance-status >70%, and life expectancy >12 weeks. Forty-three patients were enrolled (median 58 years, range 48–71). A suspension of gemcitabine 1.200 mg/m2, 2–10 ml/m2 of Lipiodol, and 5 ml of a degradable starch microsphere (Embocept) suspension, were administered intra-arterially up to 3 times with a 4-weaks-interval. Dose-limiting toxicit is defined as grade 4 thrombocytopenia, neutropenia, or nonhematologic toxicity > grade 3. Tumor response was evaluated by magnetic resonance (MRI) and computed tomography (CT) imaging. Results All patients tolerated the treatment well; with no dose limiting toxicities. Imaging follow-up according to the RECIST-criteria (Response Evaluation Criteria in Solid Tumors) revealed a partial response in 3 patients, stable disease in 16 patients and progression in 22 patients. The progression free survival was 3.3 months. A significant correlation exists only with the factor vascularization: strongly vascularized tumors show a significantly lowered response. Patients with complete or partial response and the main fraction of the stable disease group showed in the MRI and angiography only a moderate vascularization. The resulting estimate of the total survival rate amounts to a median of 10.2 months. Conclusion Transarterial chemoembolization with gemcitabine is well tolerated and provides an alternative treatment method for patients with liver metastases of breast cancer." @default.
• W2138899612 created "2016-06-24" @default.
• W2138899612 creator A5008018334 @default.
• W2138899612 creator A5022212185 @default.
• W2138899612 creator A5035318279 @default.
• W2138899612 creator A5055262652 @default.
• W2138899612 creator A5085332516 @default.
• W2138899612 creator A5085837086 @default.
• W2138899612 date "2013-12-01" @default.
• W2138899612 modified "2023-10-14" @default.
• W2138899612 title "Transarterial chemoembolisation (TACE) with gemcitabine: Phase II study in patients with liver metastases of breast cancer" @default.
• W2138899612 cites W1943102704 @default.
• W2138899612 cites W1967612488 @default.
• W2138899612 cites W1968968269 @default.
• W2138899612 cites W1977447085 @default.
• W2138899612 cites W1988507868 @default.
• W2138899612 cites W2000769678 @default.
• W2138899612 cites W2020622202 @default.
• W2138899612 cites W2034190171 @default.
• W2138899612 cites W2041976618 @default.
• W2138899612 cites W2056587438 @default.
• W2138899612 cites W2067411265 @default.
• W2138899612 cites W2071205059 @default.
• W2138899612 cites W2076339571 @default.
• W2138899612 cites W2082818260 @default.
• W2138899612 cites W2091287424 @default.
• W2138899612 cites W2093654446 @default.
• W2138899612 cites W2097189520 @default.
• W2138899612 cites W2150014310 @default.
• W2138899612 cites W2158448509 @default.
• W2138899612 cites W2165819904 @default.
• W2138899612 cites W2270490184 @default.
• W2138899612 cites W3004533979 @default.
• W2138899612 cites W4254361123 @default.
• W2138899612 doi "https://doi.org/10.1016/j.ejrad.2013.08.046" @default.
• W2138899612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24055389" @default.
• W2138899612 hasPublicationYear "2013" @default.
• W2138899612 type Work @default.
• W2138899612 sameAs 2138899612 @default.
• W2138899612 citedByCount "38" @default.
• W2138899612 countsByYear W21388996122014 @default.
• W2138899612 countsByYear W21388996122015 @default.
• W2138899612 countsByYear W21388996122016 @default.
• W2138899612 countsByYear W21388996122017 @default.
• W2138899612 countsByYear W21388996122018 @default.
• W2138899612 countsByYear W21388996122019 @default.
• W2138899612 countsByYear W21388996122020 @default.
• W2138899612 countsByYear W21388996122021 @default.
• W2138899612 countsByYear W21388996122023 @default.
• W2138899612 crossrefType "journal-article" @default.
• W2138899612 hasAuthorship W2138899612A5008018334 @default.
• W2138899612 hasAuthorship W2138899612A5022212185 @default.
• W2138899612 hasAuthorship W2138899612A5035318279 @default.
• W2138899612 hasAuthorship W2138899612A5055262652 @default.
• W2138899612 hasAuthorship W2138899612A5085332516 @default.
• W2138899612 hasAuthorship W2138899612A5085837086 @default.
• W2138899612 hasConcept C121608353 @default.
• W2138899612 hasConcept C126322002 @default.
• W2138899612 hasConcept C126838900 @default.
• W2138899612 hasConcept C197934379 @default.
• W2138899612 hasConcept C2775930923 @default.
• W2138899612 hasConcept C2776694085 @default.
• W2138899612 hasConcept C2778019345 @default.
• W2138899612 hasConcept C2778375690 @default.
• W2138899612 hasConcept C2778448856 @default.
• W2138899612 hasConcept C2778822529 @default.
• W2138899612 hasConcept C2779984678 @default.
• W2138899612 hasConcept C2780258809 @default.
• W2138899612 hasConcept C530470458 @default.
• W2138899612 hasConcept C71924100 @default.
• W2138899612 hasConceptScore W2138899612C121608353 @default.
• W2138899612 hasConceptScore W2138899612C126322002 @default.
• W2138899612 hasConceptScore W2138899612C126838900 @default.
• W2138899612 hasConceptScore W2138899612C197934379 @default.
• W2138899612 hasConceptScore W2138899612C2775930923 @default.
• W2138899612 hasConceptScore W2138899612C2776694085 @default.
• W2138899612 hasConceptScore W2138899612C2778019345 @default.
• W2138899612 hasConceptScore W2138899612C2778375690 @default.
• W2138899612 hasConceptScore W2138899612C2778448856 @default.
• W2138899612 hasConceptScore W2138899612C2778822529 @default.
• W2138899612 hasConceptScore W2138899612C2779984678 @default.
• W2138899612 hasConceptScore W2138899612C2780258809 @default.
• W2138899612 hasConceptScore W2138899612C530470458 @default.
• W2138899612 hasConceptScore W2138899612C71924100 @default.
• W2138899612 hasIssue "12" @default.
• W2138899612 hasLocation W21388996121 @default.
• W2138899612 hasLocation W21388996122 @default.
• W2138899612 hasOpenAccess W2138899612 @default.
• W2138899612 hasPrimaryLocation W21388996121 @default.
• W2138899612 hasRelatedWork W1584669207 @default.
• W2138899612 hasRelatedWork W1965395418 @default.
• W2138899612 hasRelatedWork W2024340610 @default.
• W2138899612 hasRelatedWork W2024938637 @default.
• W2138899612 hasRelatedWork W2804221754 @default.
• W2138899612 hasRelatedWork W2899528185 @default.
• W2138899612 hasRelatedWork W2899585536 @default.
• W2138899612 hasRelatedWork W3030034569 @default.
• W2138899612 hasRelatedWork W3031735911 @default.

• next